2-氨基-6-氯-4-羟基嘧啶 | 1194-21-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-6-氯-4-羟基嘧啶
• 中文别名: 2-氨基-4-氯-6-羟基嘧啶；2-氨基-4-氯-6-嘧啶甲醇；2-氨基-6-氯嘧啶-4(3H)-酮；2-氨基-6-氯-4-羟基嘧啶一水化合物
• 英文名称: 6-chloroisocytosine
• 英文别名: 2-amino-6-chloropyrimidin-4(3H)-one；2-Amino-6-chloro-4-pyrimidinol；2-amino-4-chloro-1H-pyrimidin-6-one
• CAS: 1194-21-4
• 化学式: C₄H₄ClN₃O
• mdl: MFCD00006093
• 分子量: 145.548
• InChiKey: VBWACOJLJYUFKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  252 °C (dec.)(lit.)
• 沸点：
  259.1±50.0 °C(Predicted)
• 密度：
  1.7910 (rough estimate)
• 溶解度：
  可溶于二甲基亚砜（少量）
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933599090
• RTECS号：
  UW5995000
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  请将贮藏器密封，并存放在阴凉、干燥处。确保工作间有良好的通风或排气装置。

SDS

Name:	2-Amino-6-chloro-4-pyrimidinol hydrate 95% Material Safety Data Sheet
Synonym:	4(1H)-Pyrimidinone, 2-amino-6-chloro-, hydrate
CAS:	1194-21-4

Section 1 - Chemical Product MSDS Name:2-Amino-6-chloro-4-pyrimidinol hydrate 95% Material Safety Data Sheet
Synonym:4(1H)-Pyrimidinone, 2-amino-6-chloro-, hydrate

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1194-21-4	2-Amino-6-chloro-4-pyrimidinol hydrate	95	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use extinguishing media most appropriate for the surrounding fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1194-21-4: CAS# 206658-81-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: light yellow
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 252 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H4ClN3O.xH2O
Molecular Weight: 163.55

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1194-21-4: UW5995000 CAS# 206658-81-3 unlisted.
LD50/LC50:
Not available.
Not available.
Carcinogenicity:
2-Amino-6-chloro-4-pyrimidinol anhydrous - Not listed by ACGIH, IARC, or NTP.
2-Amino-6-chloro-4-pyrimidinol hydrate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1194-21-4: No information available.
CAS# 206658-81-3: No information available.
Canada
CAS# 1194-21-4 is listed on Canada's DSL List.
CAS# 1194-21-4 is not listed on Canada's Ingredient Disclosure List.
CAS# 206658-81-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1194-21-4 is not listed on the TSCA inventory.
It is for research and development use only.
CAS# 206658-81-3 is not on the TSCA Inventory because it is a hydrate.
It is considered to be listed if the CAS number for the anhydrous form
is on the inventory (40CFR720.3(u)(2)).

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-6-氯-4-羟基嘧啶 在 甘氨酸乙酯盐酸盐 作用下， 生成 2-氨基-1,5,7,8-四氢-4,6-蝶啶二酮
  参考文献：
  名称：

  The Identification of “β-Dihydroxanthopterin” as 2,4-Diamino-6-hydroxy-p-oxazino (2,3-d)pyrimidine

  摘要：

  DOI：

  10.1021/ja01135a048
• 作为产物：
  描述：

  4,6-二氯嘧啶 在 溶剂黄146 作用下， 以 sodium hydroxide 为溶剂， 以99%的产率得到2-氨基-6-氯-4-羟基嘧啶
  参考文献：
  名称：

  Novel intermediates for the preparation of Carbovir

  摘要：

  该发明提供了一种新型的环戊烯基醇化合物，可用作制备抗艾滋病药物卡波韦的中间体。还提供了制备这种新型化合物以及利用这些化合物制备卡波韦的方法。

  公开号：

  US04939252A1
• 作为试剂：
  描述：

  2-氨基-4,6-二氯嘧啶 、 、 溶剂黄146 在 水 、 2-氨基-6-氯-4-羟基嘧啶 作用下， 以 sodium hydroxide 为溶剂， 反应 5.0h， 以This resulted in 17 g (86%) of 2-amino-6-chloropyrimidin-4(3H)-one as a white solid的产率得到2-氨基-6-氯-4-羟基嘧啶
  参考文献：
  名称：

  BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES

  摘要：

  本发明提供了用于治疗各种恶性疾病和神经退行性疾病，包括阿尔茨海默病的生物活性化合物。本文所披露的化学化合物被发现在与这些疾病相关的生物测定中表现出生物活性。提供了制药组合物、组合物的合成方法和使用该化合物、组合物和组合物治疗这些疾病的方法。

  公开号：

  US20110124634A1

文献信息

• The synthesis of 7-deazaguanines as potential inhibitors of guanosine triphosphate cyclohydrolase I
  作者：Colin L Gibson、Salvatore La Rosa、Kyuji Ohta、Peter H Boyle、Fabien Leurquin、Alexandra Lemaçon、Colin J Suckling

  DOI：10.1016/j.tet.2003.11.030

  日期：2004.1

  compounds can be prepared. These methods supplement our previous work that established routes for the synthesis of 7- and 8-substituted 7-deazaguanines. Emphasis is placed on the properties of 2-thioalkyl pyrimidines as intermediates because they provide the basis for a traceless solid-state synthesis of purines, pteridines, and their analogues. Compounds prepared have been assessed in a primary screen for

  作为GTP环水解酶I（生物合成途径中导致二氢叶酸和四氢生物蝶呤的第一个酶）的抑制剂，各种取代的7-脱氮鸟嘌呤是令人感兴趣的。描述了合成在2、6和9位（嘌呤编号）取代的7-脱氮鸟嘌呤的方法，从而可以制备各种各样的化合物。这些方法补充了我们先前的工作，该工作为合成7和8位取代的7-脱氮鸟嘌呤建立了途径。重点放在2-硫代烷基嘧啶作为中间体的性质上，因为它们为嘌呤，蝶啶及其类似物的无痕固态合成提供了基础。已经在初步筛选中评估了制备的化合物抑制GTPCH I的能力，并且已证明8-甲基脱氮鸟嘌呤比尚未描述的任何抑制剂都具有更强的效力。几种化合物似乎已通过GTPCH I进行了转化。借助于模型反应，它们的行为可以在GTPCH I的水解相机理的背景下进行解释。
• [EN] TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE TRIAZALO [4, 5-D] PYRAMIDINE ET LEUR UTILISATION COMME ANTAGONISTES DES RÉCEPTEURS DE LA PURINE
  申请人：VERNALIS R & D LTD

  公开号：WO2009156737A1

  公开（公告）日：2009-12-30

  Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

  具有化学式（I）的化合物，能够作为嘌呤受体拮抗剂的药物组合物，以及制备这些化合物的方法已被披露。这些化合物和组合物可用于治疗或预防与嘌呤受体过度功能有关的疾病。
• PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY
  申请人：The University of Tokyo

  公开号：US20170158704A1

  公开（公告）日：2017-06-08

  A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R 1 , R 2 , R 3 , R 4a , R 4c , R 5 are as defined in the description.

  根据公式（Ia）至（Ic）中的任一化合物或其药学上可接受的盐： 其中R1、R2、R3、R4a、R4c、R5如描述中所定义。
• [EN] HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA GTP CYCLOHYDROLASE 1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：HERCULES TECHNOLOGY MAN CO V INC

  公开号：WO2011035009A1

  公开（公告）日：2011-03-24

  The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

  本发明涉及小分子杂环抑制剂对GTP环化酶（GCH-I）的，或其互变异构体、前药或药用可接受盐。该发明还涉及这些化合物的药物组合物以及这些化合物用于治疗或预防疼痛（例如炎症性疼痛、伤害性疼痛、功能性疼痛或神经病理性疼痛）的医疗用途。
• [EN] BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS BIOACTIFS POUR LE TRAITEMENT DU CANCER ET DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：PONIARD PHARMACEUTICALS INC

  公开号：WO2009139834A1

  公开（公告）日：2009-11-19

  The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases.

  这项发明提供了用于治疗各种恶性疾病，如癌症和包括阿尔茨海默病在内的神经退行性疾病的生物活性化合物。本文所披露的化合物在与这些疾病相关的生物测定中显示出生物活性。提供了药物组合物、组合物和合成方法，以及使用该化合物、组合物和组合物治疗这些疾病的方法。

表征谱图